Physician profile
David Lee
NPI 1528553492
$4,853.62
in general payments reported to CMS, 2019-2025
26 companies · $764 in 2025
The $764 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.87 · 2022: $1,064 · 2023: $1,359 · 2024: $1,625 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,142 · Education: $606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,141.98 |
| Education | $605.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,052.42 | 2022-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $912.04 | 2022-2025 | |
| Abbott Laboratories | $443.86 | 2023-2024 | Ensite, Mitraclip, Aveir |
| E.R. Squibb & Sons, L.L.C. | $367.30 | 2023-2025 | Camzyos |
| Chiesi USA, INC. | $358.96 | 2022-2025 | Kengreal, Cleviprex |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $283.61 | 2022-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $230.08 | 2022-2025 | Wainua, Farxiga, Brilinta |
| Alnylam Pharmaceuticals INC. | $165.82 | 2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $155.69 | 2023-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $129.97 | 2022-2023 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $114.50 | 2024 | Inpefa |
| Bridgebio Pharma, INC. | $112.35 | 2025 | Attruby |
| Zoll Circulation INC | $100.00 | 2022 | |
| Abiomed | $94.10 | 2022-2025 | Impella |
| La Jolla Pharmaceutical Company | $72.20 | 2024-2025 | Giapreza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $49.36 | 2022-2025 | |
| Lundbeck LLC | $27.27 | 2025 | Vyepti |
| Kiniksa Pharmaceuticals International, Plc | $26.23 | 2024 | Arcalyst |
| Medtronic, INC. | $24.73 | 2022 | |
| Altathera Pharmaceuticals LLC | $24.50 | 2024 | Sotalol Hydrochloride |
| Novo Nordisk INC | $22.74 | 2024 | Ozempic |
| Vifor Pharma, INC. | $21.34 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.53 | 2021 | |
| Lantheus Medical Imaging, INC. | $19.38 | 2023 | Definity |
| Harmony Biosciences LLC | $13.77 | 2023 | Wakix |
| Cardiovascular Systems INC. | $10.87 | 2023 | Diamondback Coronary |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.